Total raised
—
Stage
Pre-Funding
Founded
2021
Headcount
6
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
GentaGel develops a local slow-release antibiotic treatment, which is injected and continuously releases antibiotics for up to 60 days. The antibiotic is not detectable in circulation but achieves sufficient therapeutic concentrations in the administered area. GentaGel provides an effective antibiotic treatment while avoiding systemic side-effects and expensive cost-of-care. The company is based on a ground-breaking drug delivery technology invented by Prof. Domb, for the in-situ sustained release of antibiotics for the treatment and prevention of surgical site infections.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesPolymers
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyHealthcareProvidersMedical Devices IndustryMedical Products
Business model
B2C
Tags
polymersantibioticspharmaceuticalsinfection